{"DataElement":{"publicId":"3855580","version":"1","preferredName":"Acute Promyelocytic Leukemia Current Response Status","preferredDefinition":"Text term to describe the acute promyelocytic leukemia response to protocol intervention as evaluated during the current period.","longName":"APLM3_CUR_RESP_ST","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3853673","version":"1","preferredName":"Acute Promyelocytic Leukemia Current Response","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the t(15;17)(q22;q12) translocation. There are two variants: the typical and microgranular variant. This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO, 2001)_Occurring in or belonging to the present time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853971v1.0:3853621v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853971","version":"1","preferredName":"APL Response","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and micro granular (hypo granular) variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001) -- 2003:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C3182:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3D61456-B55E-7082-E040-BB89AD433C9B","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853621","version":"1","preferredName":"Current Evaluation","preferredDefinition":"Occurring in or belonging to the present time.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C25471:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CBFDC0-2B34-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3D513DE-C414-C1CC-E040-BB89AD435E94","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3855491","version":"1","preferredName":"APLM3 AML Current Evaluation Response Status","preferredDefinition":"Occurring in or belonging to the present time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"APLM3_CUR_EVL_RSP_ST","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cytogenetic Complete Remission (CRc)","valueDescription":"Cytogenetic Analysis Complete Remission","ValueMeaning":{"publicId":"3854980","version":"1","preferredName":"Cytogenetic Analysis Complete Remission","longName":"3854980","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-882B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SOKKERL","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-03B9-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-03C3-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Molecular Complete Remission (CRm)","valueDescription":"Molecular Analysis Complete Remission","ValueMeaning":{"publicId":"3855308","version":"1","preferredName":"Molecular Analysis Complete Remission","longName":"3855308","preferredDefinition":"Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3EC2004-E6BD-D6FB-E040-BB89AD432FAD","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-03CD-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Morphologic Complete Remission","valueDescription":"Morphologic Finding Complete Remission","ValueMeaning":{"publicId":"3855494","version":"1","preferredName":"Morphologic Finding Complete Remission","longName":"3855494","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F09696-2BFD-3767-E040-BB89AD431888","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-03E1-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Molecular Relapse","valueDescription":"Molecular Analysis Recurrent Disease","ValueMeaning":{"publicId":"3855307","version":"1","preferredName":"Molecular Analysis Recurrent Disease","longName":"3855307","preferredDefinition":"Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3EC2004-E69A-D6FB-E040-BB89AD432FAD","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3F09696-2B7C-3767-E040-BB89AD431888","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Treatment Failure - Resistant Disease","valueDescription":"Treatment Failure Resistant Disease","ValueMeaning":{"publicId":"3855476","version":"1","preferredName":"Treatment Failure Resistant Disease","longName":"3855476","preferredDefinition":"Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Carcinoma","conceptCode":"C8511","definition":"A carcinoma that does not respond to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Failure","conceptCode":"C25745","definition":"A lack of occurrence or performance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F05B4C-AF9A-99BA-E040-BB89AD4372F4","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4EF44DE-DC56-4C6C-E040-BB89AD435952","beginDate":"2013-08-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-27","modifiedBy":"ONEDATA","dateModified":"2013-08-27","deletedIndicator":"No"},{"value":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","ValueMeaning":{"publicId":"3854971","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","longName":"3854971","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86DA-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4F0B0FB-72FB-5908-E040-BB89AD435CF5","beginDate":"2013-08-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-27","modifiedBy":"ONEDATA","dateModified":"2013-08-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865328","version":"1","preferredName":"Current Evaluation Response Status","preferredDefinition":"Occurring in or belonging to the present time.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C25471:C25214:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F295-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3F09696-2B5D-3767-E040-BB89AD431888","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 8/14/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3813676","version":"1","longName":"Response CRF","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"3813675","version":"1","longName":"Response","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Current response (APL - M3 AM","type":"Preferred Question Text","description":"Current response (APL - M3 AML)","url":null,"context":"NCI Standards"},{"name":"Prior Question Text","type":"Standard Alternate Question Text","description":"Current Response (APL - M3 AML)","url":null,"context":"NCI Standards"}],"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"E3F3FD8B-36D9-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context, updated case in question, and added registration status, CSI per Round 5 finalization task.  8/14/13 mc Created per request by CRF Harmonization Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}